Abstract
A recent report found that rare predicted loss-of-function (pLOF) variants across 13 candidate genes in TLR3- and IRF7-dependent type I IFN pathways explain up to 3.5% of severe COVID-19 cases. We performed whole-exome or whole-genome sequencing of 1,934 COVID-19 cases (713 with severe and 1,221 with mild disease) and 15,251 ancestry-matched population controls across four independent COVID-19 biobanks. We then tested if rare pLOF variants in these 13 genes were associated with severe COVID-19. We identified only one rare pLOF mutation across these genes amongst 713 cases with severe COVID-19 and observed no enrichment of pLOFs in severe cases compared to population controls or mild COVID-19 cases. We find no evidence of association of rare loss-of-function variants in the proposed 13 candidate genes with severe COVID-19 outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Columbia University COVID-19 Biobank is supported by the Vagelos College of Physicians & Surgeons Office for Research, Precision Medicine Resource (PMR), and Biomedical Informatics Resource (BMIR) of the Columbia University Irving Institute for Clinical and Translational Research (Columbia CTSA). Columbia CTSA is funded by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1TR001873. A portion of population controls were from the Washington Heights Inwood Columbia Aging Project (AG054023). Whole genome sequencing of the Biobanque Québec Covid-19 cohort was funded by the CanCOGeN HostSeq project, with contribution from the Fonds de Recherche Québec Santé (FRQS), Génome Québec, and the Public Health Agency of Canada. The Richards research group is supported by the Canadian Institutes of Health Research (CIHR), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK and the FRQS. MA and MSA acknowledge King Abdulaziz City for Science and Technology and the Saudi Human Genome Project for technical and financial support (https://shgp.kacst.edu.sa). MMR was financially supported by King Saud University, Vice Deanship of Research Chairs. GBL is supported by a joint research fellowship from Québec's ministry of health and social services, and the FRQS. TN is supported by Research Fellowships of Japan Society for the Promotion of Science (JSPS) for Young Scientists and JSPS Overseas Challenge Program for Young Researchers. JBR is supported by a FRQS Clinical Research Scholarship. This study is part of the www.covid19hg.org consortium.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The recruitment and sequencing of participants from the Columbia University COVID-19 Biobank were approved by the Columbia University IRB, protocol number AAAS7370. The genetic analyses were approved by the Columbia University IRB, under protocol number AAAS7948. The BQC-19 received ethical approval for its activities from its multicentric ethics board headed at the Centre Hospitalier de l'Université de Montréal. Recruitment of patients at the Jewish General Hospital (JGH) was also approved by the JGH ethics board. The Saudi Arabia COVID-19 Biobank study was conducted in accordance with the ethical principles of the National Bioethical committee at KACST and approved by the Institutional Review Board Committee at King Abdullah International Medical Research Centre, Ministry of National Guard-Health Affairs, Riyadh, Ministry of Health, and King Fahad Medical City. The Institutional Review Boards of all participating hospitals also approved the study. The recruitment and sequencing of participants from the Qatar Biobank (QBB) were approved by the Hamad Medical Corporation Ethics Committee in 2011 and continued with QBB Institutional Review Board (IRB) from 2017 onwards. It is renewed on an annual basis, IRB protocol number IRB-A-QBB-2019-0017. The genetic analyses presented here were approved following expedited review by the QBB Institutional Review Board under protocol number E-2020-QBB-Res-ACC-0226-0130.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Fixed author name.
Data Availability
Data are available from the corresponding authors upon reasonable request.
